GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
Raffaele MarfellaFrancesco PrattichizzoCelestino SarduPier Francesco RambaldiCarlo FumagalliLudovica Vittoria MarfellaRosalba La GrottaChiara FrigéValeria PellegriniDavide D'AndreaArturo CesaroPaolo CalabròCarmine PizziRoberto AntonicelliAntonio CerielloCiro MauroGiuseppe PaolissoPublished in: Cardiovascular diabetology (2024)
The combination of SGLT-2i and GLP-1RA is associated with a reduced incidence of cardiovascular events in patients with T2D and AMI compared with either drug used alone, with a significant effect also on peri-infarcted myocardial rescue in patients without a second event. Trial registraition ClinicalTrials.gov ID: NCT06017544.
Keyphrases
- cardiovascular events
- acute myocardial infarction
- coronary artery disease
- combination therapy
- cardiovascular disease
- end stage renal disease
- percutaneous coronary intervention
- left ventricular
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- clinical trial
- risk factors
- prognostic factors
- heart failure
- phase ii
- atrial fibrillation
- drug induced
- ankylosing spondylitis